Financings Of The Fortnight: IPO Volume Up But Post-Offering Performance Falters
This article was originally published in The Pink Sheet Daily
Some predict a washout for VC funds, too, but SV Life Sciences gathered a $523 million fund that will back 30-32 health care companies.
You may also be interested in...
It's time for The IN VIVO Blog's Third Annual Deal of the Year competition. This year, awards will be presented in three categories to highlight the most interesting and creative deal making solutions of 2010.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.